

1 Influential drivers of the cost-effectiveness of respiratory
2 syncytial virus vaccination in European older adults: A
3 multi-country analysis

4 Authors: Xiao Li¹, Lander Willem¹, Caroline Klint Johannesen², Arantxa Urchueguía-Fornes
5 ^{3,4}, Toni Lehtonen⁵, Richard Osei-Yeboah⁶, Heini Salo⁵, Alejandro Orrico Sánchez^{3,4,7}, Javier
6 Díez Domingo^{3,4,7}, Mark Jit⁸, for PROMISE investigators, Joke Bilcke¹, Harish Nair⁶, Philippe
7 Beutels¹

8
9 Affiliation:

10 ¹ Centre for Health Economics Research and Modelling Infectious Diseases (CHERMID),
11 University of Antwerp, Belgium

12 ² Department of Virology and Microbiological Special Diagnostics, Statens Serum Institut,
13 Copenhagen, Denmark

14 ³ Vaccine Research Department, Foundation for the Promotion of Health and Biomedical
15 Research in the Valencian Region (FISABIO), Valencia, Spain

16 ⁴ CIBER de Epidemiología y Salud Pública, Instituto de Salud Carlos III, Valencia, Spain

17 ⁵ Finnish Institute for Health and Welfare, Helsinki, Finland

18 ⁶ Centre for Global Health, The University of Edinburgh, Edinburgh, United Kingdom

19 ⁷ Catholic University of Valencia, Valencia, Spain.

- 1 ⁸ Department of Infectious Disease Epidemiology & Dynamics, London School of Hygiene &
- 2 Tropical Medicine
- 3
- 4 Corresponding authors
- 5 Xiao Li
- 6 Address: Centre for Health Economics Research & Modelling Infectious Diseases,
- 7 Vaccine & Infectious Disease Institute, Campus Drie Eiken (D.R.212), Universiteitsplein 1
- 8 University of Antwerp, Belgium
- 9 Email: xiao.li@uantwerpen.be

1 Abstract

2 **Background:** We aimed to identify influential drivers of the cost-effectiveness of older adult
3 respiratory syncytial virus (RSV) vaccination in Denmark, Finland, the Netherlands and
4 Valencia-Spain.

5 **Methods:** A static multi-cohort model was parameterised using country- and age-specific
6 hospitalisations using three approaches: (1) the International Classification of Diseases
7 (ICD)-coded hospitalisations, (2) laboratory RSV-confirmed hospitalisations and (3) time-
8 series modelling (TSM). Plausible hypothetical RSV vaccine characteristics were derived
9 from two protein subunit vaccines for adults aged ≥ 60 years (“60y+”). Costs and quality-
10 adjusted life-years (QALYs) were compared between four strategies: (a) “no intervention”
11 and RSV vaccination in adults (b) 60y+; (c) 65y+; (d) 75y+, from both the healthcare payers’
12 and societal perspectives. Value of information, probabilistic sensitivity and scenario
13 analyses identified influential drivers.

14 **Results:** Besides vaccine price, the hospitalisation estimates were most influential: Using
15 adjusted RSV-ICD-coded hospitalisations at a vaccine price of €150 per dose, no intervention
16 was cost-effective up to willingness-to-pay (WTP) values of €80000 per QALY gained in
17 Denmark, and up to €34000 and €62000 per QALY gained in Finland and the Netherlands,
18 respectively. Using the adjusted RSV-confirmed dataset, the findings were consistent in
19 Denmark and comparable in Finland. In Spain-Valencia, the 75y+ strategy became cost-
20 effective at WTP $>€17000$. Using TSM-based estimates, the 75y+ strategy was cost-effective
21 at WTP $>€16000$, $>€28000$, $>€13000$ and $>€37000$ in Denmark, Finland, the Netherlands and
22 Spain-Valencia, respectively. The (in-hospital) case fatality ratio and the specification of its

1 age dependency were both influential. Specifying different ways in which protective efficacy
2 waned and RSV seasons were shaped and timed had both relatively limited impact on
3 results.

4 **Conclusion:** Data gaps and uncertainties on the RSV-related burden in older adults persists
5 and influences the cost-effectiveness of RSV vaccination. More refined age- and country-
6 specific data on the RSV attributable burden are crucial to aid decision making.

7

8 **Key words:** RSV, respiratory, vaccination, policy, ageing population, economic evaluation,
9 cost-utility analysis, cost-effectiveness analysis, uncertainty

10

1 Introduction

2 Respiratory syncytial virus (RSV) is a leading cause of respiratory tract infections (RTI) in
3 both young children and older adults. Among adults aged 60 years and above (60y+), a
4 meta-analysis estimated 5.2 million RSV cases, 470000 hospitalisations and 33000 in-
5 hospital deaths across high-income countries in 2019 [1]. With ageing populations in these
6 countries, this disease burden is expected to increase.

7 RSV is contagious and seasonal, and it typically peaks during the winter months in Europe, in
8 line with several other respiratory pathogens. RSV leads to a substantial burden, exerting
9 pressure on healthcare resources [2]. The RSV-related disease burden among European
10 older adults has not been well established, in terms of country- and age-specific
11 hospitalisation rates, which are essential ingredients for cost-effectiveness analyses.
12 Previous systematic reviews included multiple studies that reported hospitalisation rates,
13 but the majority of these studies were conducted outside of Europe [1, 3].

14 Since 2023, two protein subunit RSV vaccines, Arexvy[®] (GSK) and Abrysvo[®] (Pfizer) were
15 approved for the prevention of RSV disease among adults aged 60y+ and marketed in
16 several high-income countries. In 2024, an mRNA-based vaccine mResvia[®] (Moderna) was
17 approved in the United States (US) [4]. All vaccines have demonstrated protective efficacy
18 lasting for more than one season, with waning immunity observed in the second season [5-
19 8].

20 Recommendations on RSV immunisation in older adults were made by several National
21 Immunisation Technical Advisory Groups. In the US, the Advisory Committee on
22 Immunization Practices (ACIP) recommended a single-dose RSV vaccine for all adults 75y+

1 and adults aged 60-74 years who are at increased risk for severe RSV disease [9]. In the
2 United Kingdom (UK), the Joint Committee on Vaccination and Immunisation (JCVI) advised
3 a programme for older adults aged 75 years and above (75y+)[10]. Cost-effectiveness
4 analyses were conducted to inform these ACIP and JCVI recommendations.

5 The PROMISE (Preparing for RSV Immunisation and Surveillance in Europe) Consortium
6 (<https://imi-promise.eu/>) aimed to produce new evidence on the burden of RSV disease in
7 Europe, before and after the emergence of severe acute respiratory syndrome coronavirus
8 2 (SARS-CoV-2) causing coronavirus disease 2019 (COVID-19). For instance, data on RSV
9 International Classification of Diseases (ICD)-coded and RSV-confirmed hospitalisations were
10 collected using national or regional registries in several countries. Moreover, time-series
11 modelling (TSM) was employed to estimate the RSV-attributable hospitalisations for these
12 countries.

13 We used the data on RSV hospitalisations generated by the PROMISE project to identify and
14 explore the influential parameters and assumptions driving the cost-effectiveness of RSV
15 vaccination strategies among older adults in four European countries: Denmark, Finland, the
16 Netherlands and Spain-Valencia. The choice of these countries was guided by the timely
17 availability of data of sufficient quality and detail within the PROMISE project.

18 Methods

19 Cost-effectiveness model

20 We developed a static multi-cohort model (Figure 1) named Multi-Country Model
21 Application for RSV Cost-Effectiveness policy for Adults (MCMARCELA). The modelled
22 population consists of adults aged 60 to 99 years, who were tracked monthly over a five-

1 year time horizon, which aligns with the expected maximum protective duration of RSV
2 vaccine [11]. The model considered costs and quality-adjusted life-years (QALYs) lost for RSV
3 cases seen in primary care, admitted to hospitals, and symptomatic RSV cases requiring no
4 medical attendance (non-MA). It also assumed that RSV-related mortality occurs only in a
5 hospital setting. Premature RSV-related deaths were calculated from the model using
6 hospital-fatality ratios to estimate QALYs lost over the remaining life-expectancy at the age
7 of death. The model did not separately account for RSV cases requiring only an outpatient
8 visit in hospital or an emergency department visit without admission, because such type of
9 data was not available for most of the countries considered.

10 The model made comparisons between four strategies: “no intervention” and three age-
11 based single-dose universal RSV vaccination strategies among older adults. Each vaccination
12 strategy was modelled as if a single dose were offered to everyone in an age band at the
13 same time in October, prior to the start of the first RSV season considered over the 5-year
14 time horizon:

- 15 I. 60 years and above up to 99 years (‘60y+’ strategy) based on the approved age-
16 indication,
- 17 II. 65 years and above up to 99 years (‘65y+’ strategy) considering the universal
18 influenza vaccination programmes in many European countries,
- 19 III. 75 years and above up to 99 years (‘75y+’ strategy) based on the JCVI and ACIP
20 recommendation.

21 This analysis was conducted separately from a healthcare payers’ (HCP) perspective
22 considering only direct medical costs and from a societal perspective, additionally including
23 costs associated with productivity losses of patients. Both costs and QALYs were discounted

1 at rates recommended by the country-specific pharmaco-economic guidelines (see
2 *Supplement Table 6*) [12-15].

3 [Model input parameters and assumptions](#)

4 All parameters are listed in *Supplement Table 6*, and each input parameter is described in
5 detail in *Supplement section 1.1*.

6 In brief, for Denmark, Finland and the Netherlands, RSV-ICD-coded hospitalisations by age
7 and calendar month were estimated retrospectively using national registries. The RSV-
8 confirmed data were also obtained in Denmark and Finland using the same registries [16]. In
9 Valencia, a region of Spain, the RSV-confirmed hospitalisations were collected
10 retrospectively through their regional active hospital-based surveillance network
11 (descriptions in previous publications [17, 18]). The catchment area represented 21% of the
12 overall population in Valencia (approximately 1 million), or 0.2% of the population in Spain.
13 Patients meeting preliminary inclusion criteria and meeting the influenza-like-illness (ILI)
14 case definition [19] were included and systematically tested for RSV with a multiplex
15 polymerase chain reaction (PCR) test. RSV-confirmed data was adjusted to the RSV season
16 as active surveillance was not performed throughout the whole year [16, 20]. The brief
17 description of the data collection methods is in *Supplement section 1.1.1*, and the full details
18 are available elsewhere [16].

19 Subsequently, a TSM analysis was conducted to attribute respiratory tract infection (RTI)
20 hospital admissions to RSV, using the number of positive virological isolates of respiratory
21 pathogens, including influenza A and B, SARS-CoV-2, and RSV, over time as covariates.
22 Under this approach influenza and RSV laboratory test frequency was regressed against RTI
23 incidence over time, to determine the proportion of RTI cases that were attributable to the

1 two viruses [21]. In Spain-Valencia, ILI was used instead of RTI in the TSM analysis and an
2 inference on missing weeks without active surveillance was performed in order to account
3 for the fact that data was not available throughout the whole year. The brief description of
4 the TSM analysis is in *Supplement section 1.1.1.3* and the full details are available elsewhere
5 [20].

6 To account for uncertainty on the choice of source data for the hospitalisation estimates,
7 we explored the cost-effectiveness of using (1) the RSV-ICD-coded hospitalisations with an
8 adjustment factor of 2.2 for diagnostic under-ascertainment, except for Spain-Valencia due
9 to insufficient sample size [22]. (2) the RSV-confirmed hospitalisations with the adjustment
10 factor of 2.2 (except for the Netherlands due to data unavailability), (3) the TSM estimated
11 RSV-attributable hospitalisations. The differences among the three hospitalisation datasets
12 were illustrated in *Supplement Figures 1-4*. We used the average data over three or four
13 seasons (depending on data availability) prior to the COVID-19 pandemic (2016/2017 to
14 2019/2020).

15 The RSV-related primary care episodes by age were estimated based on a meta-analysis of
16 US studies [23], which found for every RSV hospitalisation in adults aged 60y+, 8.5 RSV
17 primary care episodes occurred on average. We additionally used higher estimates of RSV-
18 related primary care episodes based on a UK modelling study in scenario analysis [24]. A
19 multi-country prospective study among European community-dwelling older adults
20 provided an estimate of 2.27 non-MA episodes per primary care episode [25, 26]. We used
21 7.13% (95% CI: 5.4-9.36) for the in-hospital case fatality ratio (hCFR) for all 60y+ based on a
22 meta-analysis [1]. The age-specific RSV-confirmed hCFRs in Finland were used in scenario
23 analysis.

1 In order to focus on identifying general drivers of cost-effectiveness of RSV vaccination
2 among older adults, and to avoid detractions due to minute interpretative differences in
3 differently defined product-specific clinical endpoints, we consider in this analysis the use of
4 a hypothetical RSV vaccine. We used plausible efficacy (mean and 95% CI) values against
5 non-MA episodes, primary care episodes, hospitalisations, and deaths by combining
6 information available at the time of the analysis for both Arexvy[®] and Abrysvo[®] (Table 1,
7 *Supplement 2.1.5*) [5, 6]. Based on waning assumptions made in published cost-
8 effectiveness analyses for older adults [27-31], we explored 13 waning scenarios
9 accommodating a range for the duration of protection from 18 months to 48 months
10 (*Supplement section 1.15*). The RSV vaccine price was assumed to be €150 per dose for all
11 countries in this study [32]. RSV vaccination coverage was based on country- and age-
12 specific influenza vaccination coverage (*Supplement Table 6*).

13 Country-specific costs were obtained for hospitalisations, including intensive care unit
14 admissions, primary care consultation, and vaccine administration (*Supplement section*
15 *1.1.7*). A cost of €4.06 per non-MA episode was used for all countries based on a European
16 multi-country prospective study [26]. From a societal perspective, the costs of productivity
17 losses were estimated using the human capital approach: the age- and country-specific daily
18 salaries were adjusted by employment rates and multiplied by the number of workdays lost.
19 We accounted for one and two lost workdays per non-MA and primary care episode,
20 respectively [33], and the country-specific length of hospital stay plus three days per
21 hospitalised case. Productivity losses due to RSV-associated premature deaths were not
22 included in order to avoid double counting [34]. All costs were inflated to their 2023 value
23 using the country-specific consumer price index (CPI) of all sectors, and those reported in
24 local currency were converted to euro (€) using the annual exchange rates of 2023 [35, 36].

1 QALY losses due to RSV deaths were estimated using remaining life expectancy at age of
2 death and standard age-specific utility values by country [37, 38] (*Supplement section 1.1.8*
3 *and Table 6*). A prospective study in European older adults estimated an average QALY loss
4 of 0.004 (95% CI: 0.001-0.010) per non-MA or primary care episode [33]. There was no
5 utility value available for individuals aged 60y+ who were hospitalised with RSV. Hence, we
6 assumed QALY losses of 0.01023 (95% CI: 0.0089-0.0170) based on another European multi-
7 country prospective study among RSV-hospitalised infants' parents [39], this value was
8 comparable to QALY losses in hospitalised influenza patients [40]. However, in scenario
9 analysis, we also assumed alternative average QALY losses of 0.0185 (CI: 0.0053-0.0347) for
10 non-hospitalised patients and 0.0193 (CI: 0.0095-0.0316) for hospitalised patients, based on
11 US ACIP meeting presentations of 2022 without full peer-reviewed publication [27].

12 Analytical approach

13 We conducted a full incremental analysis of costs and effects arising in all strategies to
14 identify the cost-effective program for willingness-to-pay (WTP) values ranging from €0 to
15 €80000 per QALY gained [41, 42].

16 To evaluate the impact of uncertain input parameters on the estimated cost-effectiveness,
17 the expected value of partial perfect information (EVPPPI) was calculated over a range of
18 WTP values through probabilistic sensitivity analysis. A probabilistic price threshold analysis
19 was also performed for each country applying the method demonstrated by Pieters and
20 colleagues [43].

21 To explore the impact of key assumptions and input parameters, we also conducted
22 deterministic scenario analyses including 13 scenarios on vaccine characteristics (i.e.,
23 efficacy, duration of protection, waning curves), and 16 scenarios on input parameters such

1 as burden of disease, QALY losses, RSV seasonality, price per dose, and the impact of the
2 COVID-19 pandemic. An overview of scenarios analyses was summarised in *Supplement*
3 *Tables 1 and 7 and section 1.4*. All analyses were conducted in R version 4.3.2.

4 Results

5 RSV health and economic burden without vaccination

6 Over a five-year time horizon, (1) using the adjusted RSV-ICD-coded dataset (*Supplement*
7 *Table 10*), we estimated 30844, 251938, and 316164 RSV cases (including non-MA, primary
8 care episodes and hospitalisations), as well as 558, 4376, and 8374 discounted QALY losses
9 among adults 60y+ in Denmark, Finland and the Netherlands, respectively. From the HCP
10 and societal perspectives, the discounted costs were €3.6 and 4.0 million in Demark, €32.1
11 and €34.5 million in Finland, and €76.2 and €90.2 million in the Netherlands, respectively.

12 (2) Using the adjusted RSV-confirmed hospitalisation dataset, the estimated RSV cases were
13 84671 in Denmark, 325860 in Finland, and 73925 in Spain-Valencia, as well as 1514, 5697,
14 and 1475 discounted QALY losses among adults 60y+ in Denmark, Finland and Spain-
15 Valencia, respectively. From the HCP and societal perspectives, the discounted costs were
16 €9.9 and 11.0 million in Demark, €41.5 and €44.7 million in Finland, and €10.6 and €10.9
17 million in Spain-Valencia, respectively.

18 (3) Using the TSM RSV-attributable estimates, we observed 24- and 9-fold higher RSV-
19 attributable cases (0.7 million) in Demark compared with the adjusted RSV-ICD-coded and
20 adjusted RSV-confirmed hospitalisations. Consequently, there were higher QALY losses and
21 direct medical and indirect medical costs. In the Netherlands, 4-fold higher RSV-attributable
22 cases (1.3 million) were estimated compared with using the adjusted RSV-ICD-coded dataset.

1 However, both in Finland and Spain-Valencia, the RSV-attributable cases from the TSM were
2 11% (289079) and 55% (33600) lower than the adjusted RSV-confirmed estimates,
3 respectively. Consequently, large differences were observed in the discounted QALY losses,
4 and the direct and indirect costs attributable to RSV. Despite the large differences in
5 baseline disease burden while using different datasets, it was consistent that the 75-84y age
6 group had the highest number of hospitalisations (except the Netherlands using adjusted
7 RSV-ICD-coded dataset); consequently, the highest number of primary care and non-MA
8 episodes, and discounted medical costs. However, the highest discounted QALY losses
9 mainly occurred in the 65-74y age group (except Spain-Valencia). Most indirect costs due to
10 productivity losses occurred in the 60-64y age group, as it had the highest active labour
11 force participation.

12 [RSV-burden averted with single-dose one-time vaccination over two years protection](#)

13 Irrespective of the hospitalisation data source, in every country the 60y+ strategy had the
14 greatest impact on disease burden in terms of cases, hospitalisations and deaths averted,
15 QALYs gained, and direct and indirect medical costs averted. However, this was also the
16 most expensive strategy with one-time vaccination costs of €195 million, €139 million, €482
17 million and €0.03 million in Denmark, Finland, the Netherlands, and Spain-Valencia,
18 respectively. Detailed RSV burden averted estimates are presented in *Supplement Tables 9*
19 *and 11* by strategy, country and methodological approach.

20 [Cost-effectiveness](#)

21 In general, more expansive vaccination strategies became cost-effective for the HCP with
22 increasing WTP values per QALY gained (Figures 2-4). A societal perspective increased the
23 potential cost savings per averted case and, therefore, it rendered more expansive

1 strategies cost-effective at lower WTP values than the HCP perspective did (*Supplement*
2 *Figures 8, 11, 14 and 15*)

3 (1) Using the adjusted RSV-ICD-coded hospitalisations (Figure 2), ‘no intervention’ was cost-
4 effective up to a WTP value of €80000 per QALY gained for the HCP in Denmark. In Finland,
5 the 75y+ and 60y+ strategies would be preferred at WTP values exceeding €34000 and
6 €40000, whereas in the Netherlands, the 65y+ and 60y+ strategy became cost-effective at
7 WTP values exceeding €62000 and €68000 per QALY gained, respectively. From the societal
8 perspective, the 65y+ strategy was dominated by the 60y+ strategy in all countries
9 (*Supplement Figure 11*).

10 (2) Using the RSV-confirmed hospitalisations (Figure 3), the finding was consistent for
11 Denmark that ‘no intervention’ is cost-effective, whereas in Finland the 75y+ and 60y+
12 strategies became preferred at lower WTP values (≥ 27000 and ≥ 30000 , respectively) versus
13 using adjusted RSV-ICD-coded hospitalisations. In Spain-Valencia, the 75y+, 65y+ and 60y+
14 strategies became cost-effective at WTP values above €17000, €25000 and €34000,
15 respectively.

16 (3) Using the TSM estimates (Figure 4), the 75y+ strategy was preferred if the WTP value
17 exceeded €16000 in Denmark, €28000 in Finland, €13000 in the Netherlands, and €36000 in
18 Spain-Valencia. The 60y+ strategy became the preferred strategy at higher WTP values of
19 €17000, €36000 in Finland, and €18000 in the Netherlands. In Spain-Valencia, the 60y+
20 strategy was not preferred up to a WTP value of €80000. Only in Denmark, the 65y+ was
21 weakly dominated by 60y+ (*Supplement Figure 9*).

1 Influence of price

2 Variations in the vaccine price from €50 to €250 per dose changed the preferred strategy
3 over a wide range of WTP levels from the HCP perspective. (1) Using the adjusted RSV-ICD-
4 coded dataset (*Supplement Figure 17*), ‘no intervention’ was cost-effective in Denmark
5 irrespective of WTP per QALY. However, at €50 per dose, in Finland the 75y+ strategy was
6 cost-effective at a WTP value of €30000, whereas in the Netherlands the 65y+ strategy
7 could be cost-effective at a WTP value of €25000. (2) Using the adjusted RSV-confirmed
8 dataset (*Supplement Figure 18*), findings are consistent in Denmark and comparable in
9 Finland versus adjusted ICD-coded hospitalisation. In Spain-Valencia, at €50 per dose, the
10 65y+ strategy would be cost-effective at a WTP value of €10000 per QALY gained. (3) Using
11 TSM estimates (*Figure 5*), the 75y+ strategy would be cost-effective at a WTP of €5000 per
12 QALY gained in Denmark and the Netherlands, €10000 in Finland, and €15000 in Spain-
13 Valencia, and the 60y+ strategy would become cost-effective at higher WTP ranges. Overall,
14 the price reductions led to sharp decreases in the WTP level at which strategies became
15 cost-effective for Denmark. This effect was less pronounced for the Netherlands and even
16 less so for Finland and Spain-Valencia. Decision uncertainty was highest nearby the WTP
17 values at which the cost-effective strategy switched.

18 Highly influential factors on the optimal strategy (other than price)

19 • Choice of datasets

20 The choice of optimal strategy at a given WTP level and price depended in all countries
21 heavily on the choice of dataset to estimate the incidence of RSV hospitalisations (RSV-ICD-
22 coded, RSV-confirmed and RSV-attributable).

23 • Hospital case fatality ratio (non-age specific and age-specific)

1 The hCFR was identified as another key driver. The EVPPI graphs demonstrated that the
2 uncertainty around the non-age-specific hCFR caused the most decision uncertainty for all
3 countries across all three datasets (Figure 6 and *Supplement Figures 10, 13 and 16*).

4 Compared with assuming non-age-specific hCFR for adults 60y+, using relatively higher
5 hCFRs among adults 75y+ made the 75y+ strategy preferred at lower WTP values, and lower
6 hCFRs in the 60-64y and 65-74y age groups made the 65y+ strategy only preferable over the
7 75y+ strategy at much higher WTP values (*Supplement Figure 20*).

8 • Adjustment factor for diagnostic under-ascertainment

9 The adjustment factor of 2.2 for diagnostic under-ascertainment of hospitalised cases was
10 also influential when using the RSV-ICD-coded and RSV-confirmed datasets (Figure 6 and
11 *Supplement Figures 10, 13, 20*). Its parametric uncertainty was as influential as that of the
12 non-age-specific hCFR when using the adjusted RSV-ICD-coded and adjusted RSV-confirmed
13 datasets (*Supplement Figures 10 and 13*).

14 • Vaccine coverage

15 RSV vaccine coverage increases in the 60-64y age group can be particularly influential for
16 the competition between the 65y+ and 60y+ strategies in countries with low baseline
17 coverage rates in the 60-64y age group (see also *Supplement Figure 20*). This is due to the
18 differences in age-specific input values for utility and hospitalisation costs for those younger
19 and older than 64 years of age and the fact that changes in coverage in 60-64y olds imply
20 different weighted average impact changes in the 60y+ age group, which do not occur in the
21 65y+ age group. For instance, if the coverage rate of 28.5% in the 60-64 y age group in
22 Denmark increased to the same level as the rate in 65y+ age group (78%), the 65y+ strategy
23 would become the preferred strategy at WTP values between €17000 and €38000 per QALY

1 gained. Hence, higher coverage in those incurring lower cost and QALY losses when ill (the
2 60-64y portion of the target group 60y+) makes the entire 60y+ age group a less optimal
3 choice for vaccination versus the other age groups (which do not include 60-64-year-olds).

4 Less influential factors on the optimal strategy

5 The duration of protective efficacy showed more impact than the type of waning curve
6 assumed (*Supplement Figure 19*). Scenarios considering a seasonal shift of RSV as observed
7 during the COVID-19 pandemic, administering RSV vaccine prior to a “mild” season and
8 applying lower vaccine efficacy in adults 80y+ all yielded negative impacts on the cost-
9 effectiveness results compared to the reference analysis. Scenarios administering RSV
10 vaccine prior to a “severe” season, using higher QALY losses associated with RSV illness and
11 a higher ratio of hospital to primary care, led to more expansive cost-effective strategies.
12 Nevertheless, these scenarios have relatively limited impacts (*Supplement Figure 15*), in the
13 context of comparing multiple age-based RSV strategies using a single RSV vaccine.

14 Discussion

15 We performed a full incremental analysis comparing no intervention and three vaccination
16 strategies in adults aged 60, 65 and 75 years and above to each other using a hypothetical
17 RSV vaccine which bridged phase 3 trial efficacy data available up to June 2024. Our
18 analyses used three hospitalisation datasets in four countries to explore the influential
19 drivers of the cost-effectiveness of RSV vaccination in European older adults. Although there
20 are substantial differences observed among countries in term of cost-effectiveness, the
21 influential drivers are consistent across countries. We found that apart from the vaccine
22 price, the key driver of decision uncertainty regarding which strategy is cost-effective in all

1 countries is the choice of the RSV hospital admissions dataset to use. The second most
2 important uncertainty driver is the non-age-specific hCFR and the adjustment for diagnostic
3 under-ascertainment of hospitalised cases, when using the adjusted RSV-ICD-coded and
4 RSV-confirmed datasets as they were co-related.

5 Since RSV clinical symptoms are indistinguishable from those of many other respiratory
6 virus infections and laboratory testing for RSV is relatively rare in older European adults,
7 RSV-ICD-coded hospitalisation rates can substantially underestimate the disease burden,
8 especially in countries without routine RSV testing [25, 44]. We, therefore, investigated the
9 impact of using RSV-ICD-coded (except Spain-Valencia), RSV-confirmed (except the
10 Netherlands), or TSM model-based RSV-attributable hospitalisations to inform RSV
11 hospitalisation rates. We showed this impact to be very high. For instance, after applying an
12 adjustment factor of 2.2 to the RSV-ICD-coded hospitalisations and RSV-confirmed, no
13 intervention was cost-effective up to the WTP value of €80000 per QALY gained in Denmark,
14 and up to €34000 and €27000 per QALY gained in Finland. No intervention was cost-
15 effective up to a WTP value of €62000, and €17000 per QALY gained in the Netherlands
16 (using adjusted RSV-ICD-coded hospitalisations) and Spain-Valencia (using adjusted RSV-
17 confirmed hospitalisations), respectively. However, model-based analyses of TSM data
18 yielded increased age-specific RSV attributability, and when using the resulting
19 hospitalisation rates, the 75y+ strategy was shown to be cost-effective at much lower WTP
20 values per QALY gained, except Spain-Valencia.

21 The TSM-based approach used in this analysis is a method commonly used to estimate the
22 burden of many other diseases such as influenza [45]. In our analysis, we used laboratory
23 test data series on four pathogens (influenza A, influenza B, SARS-CoV-2 and RSV) that cause

1 RTIs (in Spain-Valencia, ILI was used as a proxy for RTI). Although these are four highly
2 important pathogens for RTIs, this is not an exhaustive inclusion of potential causative
3 pathogens and, therefore, the attributable fractions estimated for each or some of these
4 pathogens to RTI hospitalisation may be overestimations, although this was partially
5 adjusted for by including a constant term. On the other hand, RSV-ICD-coded hospital
6 admission data are likely to substantially underestimate RSV-related hospital admissions [44,
7 46]. RSV diagnostic tests were also not systematically performed except in Spain-Valencia.
8 When adjusting RSV-ICD-coded and RSV-confirmed datasets with the diagnostic under-
9 ascertainment factor of 2.2, the findings were substantially different than those using TSM
10 estimates in Denmark. The large differences were also observed in the Netherlands when
11 comparing the adjusted RSV-ICD-coded hospitalisation with the TSM estimates. However,
12 the results of using three datasets were comparable in Finland. In Spain-Valencia, the
13 adjusted-RSV-confirmed dataset showed more favourable results for RSV vaccination. This
14 could be explained by the fact that testing was already systematic in all included in patients
15 in Spain-Valencia. However, the use of ILI as inclusion criteria (in Spain-Valencia) is known to
16 underestimate the real RSV burden in the surveillance networks compared to other case
17 definitions an under-ascertainment that has not been corrected for here [25, 47, 48]. Hence,
18 the adjustment factor and its uncertainty need to be interpreted with caution, taking into
19 account country-specific coding and testing practices.

20 Moreover, the hCFR and the specification of its age dependency were influential
21 (*Supplement Figures 10, 13, 15 and 20*). Despite the efforts to link the RSV-confirmed deaths
22 with hospital and mortality registries of multiple countries, we were only able to use the
23 age-specific hCFR for Finland, which had a sufficient sample size and was compliant with the
24 applicable data privacy law. Importantly, we demonstrated that acknowledging the age-

1 dependent nature of the hCFR is important when selecting optimal age-based RSV
2 vaccination strategies in older adults.

3 Our price threshold analysis showed that different “vaccine price per dose” thresholds exist
4 for different “WTP per QALY” levels, implying different optimal choices of strategies. When
5 considering vaccination strategies among 60y+, 65y+ and 75y+, the strategy protecting the
6 oldest (75y+) age group is first selected from the HCP perspective. With increasing WTP
7 values or decreases in price, the 65y+ and 60y+ strategies can become the optimal strategy.
8 Embedded in our calculations is the budget impact. Clearly, the smaller older-age cohorts
9 have a budgetary advantage over larger younger-age ones. In many countries, budget-
10 impact considerations may determine the choice of preferred strategy as much as cost-
11 effectiveness considerations do. For instance, Hodgson and colleagues assumed one year
12 protection and estimated the threshold price at which the 75y+ strategy can be cost-
13 effective at a much higher price (£20.71) than the price (£3.63) at which it would be
14 considered affordable, given a UK-set budget constraint for an individual programme of £20
15 million annually during the first three years of implementation [49].

16 The extensive exploration of different shapes of waning and protective duration types of
17 showed it has limited impact on the potential for a cost-effective result for a single RSV
18 vaccine. However, it can become more important in head-to-head comparisons of different
19 vaccine brands, especially so when vaccines compete more on marginal differences in age-
20 specific protective efficacy over time than on more influential differences in price-setting.

21 Given the trial-based information available, with different case definitions of the clinical
22 endpoints of the licensed vaccines, such a head-to-head comparison is beyond the scope of
23 this paper.

1 We assumed the RSV vaccines would be administered prior to the expected RSV season in
2 Europe in October (with instant protection) in order to maximise the effectiveness.
3 However, depending on the country, influenza, pneumococcal and COVID-19 vaccines are
4 also typically administered in the last quarter of the calendar year in the same target
5 populations, which can lead to implementation challenges for RSV vaccines due to crowded
6 schedules. Given that RSV vaccines protect longer than one season, a year-round
7 programme might be considered, possibly together with the pneumococcal or herpes zoster
8 vaccine among older adults. However, given the clear seasonal pattern of RSV in Europe, a
9 year-round programme would be less effective than a seasonal programme due to waning
10 protection. Moreover, the coverage of pneumococcal vaccines is generally lower than the
11 coverage of influenza vaccines among adults 65 years and above in Europe. Joint advice for
12 RSV, influenza and COVID-19 vaccine before the winter might simplify the communication
13 and, hence, achieve higher coverage.

14 This is the first analysis that assessed the cost-effectiveness of three age-based RSV
15 vaccination strategies among older adults in more than two countries and identified the key
16 evidence gaps that were most influential to cost-effectiveness. Previous analyses on a single
17 country or two countries did not explore the sensitivity to different data sources, the
18 influence of a shift in seasonality and the severity of a season [29, 30, 40, 49, 50]. Our
19 results are comparable with two cost-effectiveness analyses published in 2023, which
20 applied vaccine protection over two RSV seasons. Moghadas and colleagues evaluated both
21 marketed RSV vaccines in the US among adults aged 60y+. They concluded that both
22 vaccines can be cost-effective at a price of \$235 (~€219) and \$245 (~€228) per dose given a
23 WTP value of \$95000 (~€88000) per QALY gained, with sensitivity analyses on WTP values of
24 \$80000 (~€75000) and \$120000 (~110000) per QALY gained [29]. Using the time-series

1 estimates, our study showed that if the RSV vaccine is priced at €250 per dose, the 60y+
2 strategy can be cost-effective at WTP values of €30000 and €35000 per QALY gained in
3 Denmark and the Netherlands, respectively. We used age-specific hospitalisation rates,
4 which led to much higher estimates for the 85y+ age group (~366 per 100000 in the
5 Netherlands and 533 per 100000 in Denmark) in comparison to the US study (214 per
6 100000 for any adult aged 60y+, with a 54.8% proportion in 85y+). Wang and colleagues
7 conducted a cost-effectiveness analysis in Hong Kong and used adjusted hospitalisation
8 rates ranging from 23.0 to 221.4 per 100000 in the 60-64y and 75y+ age groups, respectively
9 [30]. By adjusting ICD-coded hospitalisations, our analysis estimated a lower rate in
10 Denmark (4.2 and 17.8 per 100000), the Netherlands (0.4 and 2.2 per 100000) and Spain
11 (2.6 and 13.1 per 100000), but a higher rate in Finland (37.1 and 168.0 per 100000). The
12 Hong Kong analysis also generally highlighted the price and disease burden as influential
13 drivers for the cost-effectiveness analysis, as did previous analyses, which assumed
14 protection over one RSV season [40, 49, 50].

15 Unlike in the UK, where the WTP thresholds of £20000 (~€24000) and £30000 (~€35000) per
16 QALY gained from the National Health Service (NHS) perspective are clearly indicated, the
17 four European countries in our analysis do not have an explicit WTP reference value [51]. In
18 Denmark, a WTP value of DKK 88000 (~€12000) per QALY gained was estimated via a
19 population survey in 2001, which might need updating [52]. In Finland, infant varicella,
20 pneumococcal and rotavirus vaccination programmes were considered to be cost-effective
21 at WTP values ranging from €15000 to €25000 per QALY gained from HCP perspective [53].
22 In the Netherlands, the reference values of €20000, €50000 and €80000 per QALY gained
23 depended on the disease severity and perspective [54]. In Spain, a threshold of €30000 from
24 the NHS perspective is commonly cited [55]. Instead of using one or multiple arbitrary

1 threshold values, our analysis presented findings over a range of WTP values (€0-80000 per
2 QALY gained) to assess the influence of the WTP value on the optimal choice.

3 Our study has some additional strengths. It used the most recent country-specific data to
4 populate the model according to country-specific pharmacoeconomic guidelines.

5 Considerable differences in the RSV health and economic burden exist between countries,
6 and policy makers should reflect on these when making decisions. Most strikingly, RSV

7 seasonality changed during the COVID-19 pandemic in many countries. Therefore, we

8 simulated an off-season hospital admission peak (four months earlier) observed during the
9 pandemic and found the results would be less favourable because administering RSV

10 vaccine in October would miss either a portion or the entirety of the seasonal peak. On top

11 of that, we also investigated introducing RSV vaccine in a country with a biannual seasonal
12 pattern and found whether the vaccine was introduced first in a “severe” or in a “mild”

13 season had relatively little impact. This result seems a consequence of protective efficacy

14 remaining substantial in the second season. Furthermore, we explored multiple vaccine

15 efficacy waning scenarios in combination with duration of protection based on the latest

16 clinical data and demonstrated that the duration of protection tends to have more impact

17 than the type of waning curve assumed. Finally, extensive sensitivity analyses were

18 performed using a wide range of WTP values to investigate the sensitivity of the optimal

19 choice of strategy to the adopted WTP level.

20 An important limitation of our analysis is that we investigated age-based and not risk group-

21 based strategies. We investigated one-time RSV vaccination, but did not attempt to model

22 scenarios with repetitive vaccination of cohorts over time. Future refined information on

23 vaccine effectiveness and durability may allow the evaluation of such strategies realistically

1 in future. Moreover, hCFR was used to estimate RSV-related deaths in the inpatient setting.
2 However, deaths that occurred in community setting (i.e., nursing home) were not captured
3 due to data availability, hence, it might underestimate cost-effectiveness of the RSV vaccine.
4 There are a few other limitations. Due to data limitations, the hospitalisation rate of a wide
5 age group (18-64 years) was applied to a small subgroup (60-64 years) in all four countries
6 when using TSM estimates. However, the impact on the overall insights from this analysis
7 was negligible. We were unable to explicitly evaluate the impact of potentially
8 disproportionately prevented re-admissions, long-term consequences due to RSV
9 hospitalisation (e.g., transfer to a nursing home instead of home after discharge), RSV
10 vaccine's potential prevention of exacerbations of chronic respiratory disease and cardiac
11 events [56], and productivity losses of caregivers under the societal perspective, mainly
12 because the occurrence of, and effectiveness against, these endpoints were unavailable.

13 Conclusion

14 Large data gaps and uncertainties around the RSV burden among older adults persist in
15 many European countries, contributing to substantial uncertainties regarding the cost-
16 effectiveness of intervention programs. Given that these countries need to make urgent
17 decisions about RSV vaccination, more refined age-, risk group-, and country-specific RSV
18 burden data are crucial. Evidence-based vaccine introduction decisions will require greater
19 investment in enhanced RSV surveillance and better data linkage systems to enable
20 accurate assessments of the age- and country-specific RSV burden, especially in tertiary and
21 primary care settings, such as those established in Finland. Without this, costly and
22 potentially suboptimal decisions risk being made, leading to substantial opportunity costs
23 due to the large target populations to be vaccinated.


1 Figures and Tables

2 *Table 1: Phase 3 vaccine efficacy data of Arexvy® and Abrysvo® and the efficacy values of an RSV hypothetical vaccine.*

Arexvy® (GSK)			Abrysvo® (Pfizer)		
Endpoints	Season 1 (full season)	Season 2 (full season)	Endpoints	Season 1 (full season)	Season 2 (full season)
			ARI ≥1 symptom	62.1% (95% CI:37.1-77.9)	Not shared in public domain yet
ARI ≥2 symptoms or sign	71.7% (95% CI: 56.2-82.3)	40.6% (95% CI: 19.0–57.0)			
LRTD ≥2 symptoms including ≥1 sign or ≥3 symptoms	82.6% (96.95% CI: 57.9-94.1)	56.1% (95% CI: 28.2-74.4)	LRTD ≥2 symptoms or signs	66.7% (96.66% CI: 28.8-85.8)	55.7% (95% CI: 34.7-70.4)
			LRTD ≥3 symptoms or signs	85.7% (96.66% CI: 32-98.7)	77.8% (95% CI: 51.4-91.1)
Severe LRTD (≥2 signs or defined as severe by investigator)	94.1% (95% CI: 62.4-99.9)	64.2% (95% CI: 61.6-93.4%)			
RSV hypothetical vaccine					
Vaccine efficacy against		Season 1 (full season)		Season 2 (full season)	
Non-MA		65% (35–85%)		35% (15-60%)	
Primary care		65% (35–85%)		35% (15-60%)	
Hospitalisation		80% (35-95%)		55% (25-80%)	
Death		90% (60-100%)		60% (55-95%)	

3 *Abbreviations: ARI: acute respiratory infection, LRTD: lower respiratory tract disease*


4 *Figure 1: Model structure.*



5

6 *Footnote: primary care visits were estimated from hospitalisations, and non-medical attendance were estimated from primary care visits.*

1 *Figure 2: Using adjusted RSV-ICD-coded disease burden: preferred strategy based on cost-effectiveness analysis from the*
 2 *healthcare payers' perspective.*




3

4 *Note: The RSV vaccine price per dose assumed is €150.*

5 *Abbreviations: QALY: quality-adjusted life-year, EUR: euro*

6

7 *Figure 3: Using adjusted RSV-confirmed disease burden: preferred strategy based on cost-effectiveness analysis from the*
 8 *healthcare payers' perspective.*



9
10


Note: The RSV vaccine price per dose assumed is €150. Spain: Valencia region in this analysis

11

Abbreviations: QALY: quality-adjusted life-year, EUR: euro

12

- 1 *Figure 4: Using time-series-modelling RSV estimates: preferred strategy based on cost-effectiveness analysis from the*
- 2 *healthcare payers' perspective.*




3

4 *Note: The RSV vaccine price per dose assumed is €150. Spain: Valencia region in this analysis)*

5 *Abbreviations: QALY: quality-adjusted life-year, EUR: euro*

6


- 1 Figure 5: Using TSM estimates: Price threshold analysis showing the cost-effective strategy at different WTP thresholds
- 2 from HCP's perspective.



3 Abbreviation: TSM: time-series modelling; HCP: healthcare payers' perspective; QALY: quality-adjusted life-year

4

1 *Figure 6: Expected value of partial perfect information for Finland, using three different hospitalisation datasets.*



2 *Abbreviations: RSV: respiratory syncytial virus; TSM: time-series modelling, QALY: quality-adjusted life-year*

3

4 List of abbreviation

5 ACIP: Advisory Committee on Immunization Practices

6 CI: confidence interval

7 COVID-19: coronavirus disease 2019

8 CPI: consumer price index

9 EVPPPI: expected value of partial perfect information

- 1 hCFR: in-hospital case fatality ratio
- 2 HCP: healthcare payer
- 3 ICD: International Classification of Diseases
- 4 ILI: influenza-like-illness
- 5 JCVI: Joint Committee on Vaccination and Immunisation
- 6 MA: medical attendance
- 7 MCMARCELA: Multi-Country Model Application for RSV Cost-Effectiveness policy for Adults
- 8 PCR: polymerase chain reaction
- 9 PROMISE: Preparing for RSV Immunisation and Surveillance in Europe
- 10 QALY: quality-adjusted life-years
- 11 RSV: respiratory syncytial virus
- 12 SARS-CoV-2: severe acute respiratory syndrome coronavirus 2
- 13 TSM: time-series modelling
- 14 UK: United Kingdom
- 15 US: United States
- 16 WTP: willingness-to-pay
- 17 Y: year

1 Declarations

2 Ethics approval and consent to participate

3 Not applicable

4 Consent for publication

5 Not applicable

6 Availability of data and materials

7 Almost all the data analysed and generated during this study are included in this published
8 article and its supplementary files. Formal requests for additional data can be made to the
9 corresponding author (XL) or the senior authors (PB).

10 Funding

11 This project has received funding from the Innovative Medicines Initiative 2 Joint
12 Undertaking (JU) under grant agreement number 101034339. The JU receives support from
13 the European Union's Horizon 2020 research and innovation program and European
14 Federation of Pharmaceutical Industries Associations. MJ received funding from the NIHR
15 Health Protection Research Units in Modelling and Health Economics (NIHR200908) and
16 Immunisation (NIHR200929).

17 The funders of the study had no role in study design, data collection, data analysis, data
18 interpretation, or writing of the report.

19 Competing interests

20 Outside the submitted work, PB declares funding received by his institute from Merck for
21 research on varicella-zoster and Pfizer for research on pneumococcus vaccine, XL declares

1 funding received by her institute from Icosavax, but they have not received any personal
2 fees or other personal benefits. CKJ reports a research grant from Nordsjællands Hospital,
3 travel grants from the University of Copenhagen, William Demants Fond in Denmark, and
4 the European Society of Clinical Virology and expert consultation fees from Sanofi, outside
5 of the submitted work. Outside the submitted work, HN declares consulting fees received
6 from WHO, Pfizer, Bill and Melinda Bill and Melinda Gates Foundation and Sanofi,
7 honoraria for lectures/presentations from Astra Zeneca, GSK and Pfizer paid to his
8 institution, travel grants from Pfizer and Sanofi, and participation on a Data Safety
9 Monitoring Board or Advisory Board of GSK, Sanofi, Merck, Icosavax, Pfizer (paid to his
10 institution), as well as WHO and ResViNET (unpaid). AUF declares grants/contracts from
11 Moderna and VAC4EU paid to her institution, outside submitted work. AOS and JDD
12 declares grants/contracts from Moderna, MSD and GSK paid to their institution, outside
13 submitted work. AOS also declares consultancy fees from GSK and Moderna,
14 outside submitted work. JDD declares consultancy fees and honoraria from GSK, Pfizer and
15 MSD, and travel grants from Sanofi and GSK, outside the submitted work. HS declares
16 attending Adult Immunization Board meetings twice a year, the meetings (and travel) are
17 funded by an unrestricted grant from Vaccines Europe, outside submitted work. LW
18 declares grants received from Research Foundation Flanders (FWO), Antwerp University
19 Research Council and Horizon Europe 2.1 – Health paid to his institute, outside the
20 submitted work. MJ declares research grants from NIHR, RCUK, BMGF, WHO, Gavi,
21 Wellcome Trust, European Commission, InnoHK, TFGH, CDC, Gates Foundation paid to his
22 institution, outside the submitted work.
23 Other authors declared no competing interests.

1

2

3 Authors' contributions

4 PB and HN initiated and supervised the study. XL, LW, JB and PB conceptualised the study.
5 XL analysed input data, performed literature searches and auxiliary data collection. XL, LW
6 and JB wrote the cost-effectiveness model codes. XL performed the cost-effectiveness
7 analyses. CKJ, AUF, and LT conducted national/regional database analyses, and collected
8 and validated data in Denmark, Spain-Valencia, and Finland, respectively. CKJ, ROY, and TL
9 led and estimated the time-series model-based hospitalisations. HS, AOS and JDD provided
10 implementation, resource use and cost data for Finland and Spain. HN, MJ, JB and PB
11 advised on model parameters, intervention characteristics and scenario analyses. XL, LW, JB
12 and PB wrote the initial manuscript draft. All authors critically reviewed the manuscript and
13 provided final approval of the manuscript.

14 Acknowledgements

15 PROMISE investigators: Harish Nair and Harry Campbell (University of Edinburgh, Edinburgh,
16 UK); Louis Bont (University Medical Centre, Utrecht, the Netherlands); Philippe Beutels
17 (University of Antwerp, Antwerp, Belgium), Peter Openshaw (Imperial College, London, UK),
18 Andrew Pollard (University of Oxford, Oxford, UK), Hanna Nohynek (Finnish Institute for
19 Health and Welfare, Helsinki, Finland), John Paget (Netherlands Institute for Health Services
20 Research, Utrecht, Netherlands), Eva Molero (Teamit Research S.L., Barcelona, Spain), Javier
21 Díez-Domingo (Vaccine Research Department, FISABIO-Public Health and CIBERESP, ISCIII,
22 Valencia, Spain), Rolf Kramer (Sanofi Pasteur, Lyon, France), Jim Janimak (GlaxoSmithKline,
23 Wavre, Belgium), Veena Kumar (Novavax, Gaithersburg, Maryland, United States), Elizabeth

- 1 Begier (Pfizer Limited, New York City, New York, United States), Jenny Hendri (Janssen,
- 2 Beerse, Belgium).
- 3 The authors would like to thank You Li, Valerie Sankatsing and Matthieu Beuvelet for their
- 4 critical review of our study report and valuable comments.
- 5

1 Reference

- 2 1. Savic M, Penders Y, Shi T, Branche A, Pircon JY: **Respiratory syncytial virus disease**
3 **burden in adults aged 60 years and older in high-income countries: A systematic**
4 **literature review and meta-analysis.** *Influenza Other Respir Viruses* 2023,
5 **17(1):e13031.**
- 6 2. Li Y, Wang X, Broberg EK, Campbell H, Nair H, European RSVSN: **Seasonality of**
7 **respiratory syncytial virus and its association with meteorological factors in 13**
8 **European countries, week 40 2010 to week 39 2019.** *Euro Surveill* 2022, **27(16).**
- 9 3. Shi T, Vennard S, Jasiewicz F, Brogden R, Nair H: **Disease Burden Estimates of**
10 **Respiratory Syncytial Virus related Acute Respiratory Infections in Adults With**
11 **Comorbidity: A Systematic Review and Meta-Analysis.** *J Infect Dis* 2022, **226(Suppl**
12 **1):S17-s21.**
- 13 4. Wilson E, Goswami J, Baqui AH, Doreski PA, Perez-Marc G, Zaman K, Monroy J,
14 Duncan CJA, Ujiie M, Ramet M *et al*: **Efficacy and Safety of an mRNA-Based RSV**
15 **PreF Vaccine in Older Adults.** *N Engl J Med* 2023, **389(24):2233-2244.**
- 16 5. Walsh EE, Pérez Marc G, Zareba AM, Falsey AR, Jiang Q, Patton M, Polack FP, Llapur
17 C, Doreski PA, Ilangovan K *et al*: **Efficacy and Safety of a Bivalent RSV Prefusion F**
18 **Vaccine in Older Adults.** *N Engl J Med* 2023, **388(16):1465-1477.**
- 19 6. Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF,
20 van Zyl-Smit RN, Campora L, Dezutter N *et al*: **Respiratory Syncytial Virus Prefusion F**
21 **Protein Vaccine in Older Adults.** *N Engl J Med* 2023, **388(7):595-608.**
- 22 7. Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I,
23 Martinon-Torres F, Schwarz TF, van Zyl-Smit RN *et al*: **Efficacy and safety of**
24 **respiratory syncytial virus prefusion F protein vaccine (RSVPref3 OA) in older**
25 **adults over 2 RSV seasons.** *Clin Infect Dis* 2024.
- 26 8. **Pfizer Announces Positive Top-Line Data for Full Season Two Efficacy of ABRYSCO®**
27 **for RSV in Older Adults** [[https://www.pfizer.com/news/press-release/press-release-](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two)
28 [detail/pfizer-announces-positive-top-line-data-full-season-two](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-positive-top-line-data-full-season-two)]
- 29 9. **ACIP Recommendations**
30 [<https://www.cdc.gov/vaccines/acip/recommendations.html>]
- 31 10. **Respiratory syncytial virus (RSV) immunisation programme: JCVI advice, 7 June**
32 **2023** [[https://www.gov.uk/government/publications/rsv-immunisation-programme-](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023)
33 [jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023)
34 [jcvi-advice-7-june-2023](https://www.gov.uk/government/publications/rsv-immunisation-programme-jcvi-advice-7-june-2023/respiratory-syncytial-virus-rsv-immunisation-programme-jcvi-advice-7-june-2023)]
- 35 11. Van Effelterre T, Hens N, White LJ, Gravenstein S, Bastian AR, Buyukkaramikli N,
36 Cheng CY, Hartnett J, Krishnarajah G, Weber K *et al*: **Modeling Respiratory Syncytial**
37 **Virus Adult Vaccination in the United States With a Dynamic Transmission Model.**
38 *Clin Infect Dis* 2023, **77(3):480-489.**
- 39 12. Alban A, Gyldmark M, Pedersen AV, Sogaard J: **The Danish approach to standards**
40 **for economic evaluation methodologies.** *Pharmacoeconomics* 1997, **12(6):627-636.**

- 1 13. **Preparing a Health Economic Evaluation to Be Attached to the Application for**
2 **Reimbursement Status and Wholesale Price for a Medicinal Product. Application**
3 **Instructions (December 2019)**
4 [\[https://tools.ispor.org/PEguidelines/source/2011Pricing_Board_Guidance_HEvaluation_english.pdf\]](https://tools.ispor.org/PEguidelines/source/2011Pricing_Board_Guidance_HEvaluation_english.pdf)
5
- 6 14. Hakkaart-van Roijen L, Peeters S, Kanters T: **Kostenhandleiding voor economische**
7 **evaluaties in de gezondheidszorg: Methodologie en Referentieprijzen (Herziene**
8 **versie 2024)**. In. Edited by Institute for Medical Technology Assessment Erasmus
9 Universiteit Rotterdam. Online; 2024.
- 10 15. Lopez Bastida J, Oliva J, Antonanzas F, Garcia-Altes A, Gisbert R, Mar J, Puig-Junoy J:
11 **[A proposed guideline for economic evaluation of health technologies]**. *Gac Sanit*
12 2010, **24**(2):154-170.
- 13 16. **PROMISE deliverable: D1.6 RSV healthcare burden in young children and the**
14 **elderly in 6 European countries before and since the emergence of the COVID-19**
15 **pandemic** [www.ed.ac.uk/sites/default/files/atoms/files/pr0a0d_1.pdf]
- 16 17. Mira-Iglesias A, Demont C, Lopez-Labrador FX, Mengual-Chulia B, Garcia-Rubio J,
17 Carballido-Fernandez M, Tortajada-Girbes M, Mollar-Maseres J, Schwarz-Chavarri G,
18 Puig-Barbera J *et al*: **Role of age and birth month in infants hospitalized with RSV-**
19 **confirmed disease in the Valencia Region, Spain**. *Influenza Other Respir Viruses*
20 2022, **16**(2):328-339.
- 21 18. Mira-Iglesias A, Lopez-Labrador FX, Guglieri-Lopez B, Tortajada-Girbes M, Baselga-
22 Moreno V, Cano L, Mollar-Maseres J, Carballido-Fernandez M, Schwarz-Chavarri G,
23 Diez-Domingo J *et al*: **Influenza vaccine effectiveness in preventing hospitalisation**
24 **of individuals 60 years of age and over with laboratory-confirmed influenza,**
25 **Valencia Region, Spain, influenza season 2016/17**. *Euro Surveill* 2018, **23**(8).
- 26 19. The European Commission: **DECISIONS COMMISSION IMPLEMENTING DECISION (EU)**
27 **2018/945 of 22 June 2018** *Official Journal of the European Union* 2018.
- 28 20. **PROMISE deliverable: D1.7 Report on impact of COVID-19 and COVID-19 NPIs on**
29 **RSV healthcare burden**
30 [[www.ed.ac.uk/sites/default/files/atoms/files/promise_d1.7_report_on_impact_of](http://www.ed.ac.uk/sites/default/files/atoms/files/promise_d1.7_report_on_impact_of_covid-19_and_covid-19_npis_on_rsv_healthcare_burden_v1.0.pdf)
31 [covid-19 and covid-19 npis on rsv healthcare burden v1.0.pdf](http://www.ed.ac.uk/sites/default/files/atoms/files/promise_d1.7_report_on_impact_of_covid-19_and_covid-19_npis_on_rsv_healthcare_burden_v1.0.pdf)]
- 32 21. Johannesen CK, van Wijhe M, Tong S, Fernandez LV, Heikkinen T, van Boven M,
33 Wang X, Boas H, Li Y, Campbell H *et al*: **Age-Specific Estimates of Respiratory**
34 **Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series**
35 **Analysis**. *J Infect Dis* 2022.
- 36 22. Li Y, Kulkarni D, Begier E, Wahi-Singh P, Wahi-Singh B, Gessner B, Nair H: **Adjusting**
37 **for Case Under-Ascertainment in Estimating RSV Hospitalisation Burden of Older**
38 **Adults in High-Income Countries: a Systematic Review and Modelling Study**. *Infect*
39 *Dis Ther* 2023, **12**(4):1137-1149.
- 40 23. McLaughlin JM, Khan F, Schmitt HJ, Agosti Y, Jodar L, Simoes EAF, Swerdlow DL:
41 **Respiratory Syncytial Virus-Associated Hospitalization Rates among US Infants: A**
42 **Systematic Review and Meta-Analysis**. *J Infect Dis* 2020.

- 1 24. Fleming DM, Taylor RJ, Lustig RL, Schuck-Paim C, Haguinet F, Webb DJ, Logie J,
2 Matias G, Taylor S: **Modelling estimates of the burden of Respiratory Syncytial virus**
3 **infection in adults and the elderly in the United Kingdom.** *BMC Infect Dis* 2015,
4 **15**:443.
- 5 25. Korsten K, Adriaenssens N, Coenen S, Butler C, Ravanfar B, Rutter H, Allen J, Falsey A,
6 Pircon JY, Gruselle O *et al*: **Burden of respiratory syncytial virus infection in**
7 **community-dwelling older adults in Europe (RESCEU): an international prospective**
8 **cohort study.** *Eur Respir J* 2020.
- 9 26. Mao Z, Li X, Korsten K, Bont L, Butler C, Wildenbeest J, Coenen S, Hens N, Bilcke J,
10 Beutels P: **Economic Burden and Health-Related Quality of Life of Respiratory**
11 **Syncytial Virus and Influenza Infection in European Community-Dwelling Older**
12 **Adults.** *J Infect Dis* 2022, **226**(Suppl 1):S87-s94.
- 13 27. Hutton DW: **Economic Analysis of RSV Vaccination in Older Adults.** In: *ACIP*
14 *Presentation Slides: June 21-23, 2023 Meeting: 2023*; 2023.
- 15 28. Ortega-Sanchez IR: **Economics of Vaccinating U.S. Adults ≥60 years-old against**
16 **Respiratory Syncytial Virus.** In: *ACIP Presentation Slides: June 21-23, 2023 Meeting:*
17 *2023*; 2023.
- 18 29. Moghadas SM, Shoukat A, Bawden CE, Langley JM, Singer BH, Fitzpatrick MC, Galvani
19 AP: **Cost-effectiveness of Prefusion F Protein-based Vaccines Against Respiratory**
20 **Syncytial Virus Disease for Older Adults in the United States.** *Clin Infect Dis* 2023.
- 21 30. Wang Y, Fekadu G, You JHS: **Comparative Cost-Effectiveness Analysis of Respiratory**
22 **Syncytial Virus Vaccines for Older Adults in Hong Kong.** *Vaccines (Basel)* 2023,
23 **11**(10).
- 24 31. Bilcke J, Ogunjimi B, Hulstaert F, Van Damme P, Hens N, Beutels P: **Estimating the**
25 **age-specific duration of herpes zoster vaccine protection: a matter of model choice?**
26 *Vaccine* 2012, **30**(17):2795-2800.
- 27 32. GSK: **Arexvy product leaflet (ESWI conference).** In: The European Scientific Working
28 Group on Influenza (ESWI) 2023.
- 29 33. Mao Z, Li X, Dacosta A, Billard M, Wildenbeest J, Korsten K, Bont L, Martínón-Torres F,
30 Heikkinen T, Cunningham S *et al*: **Costs and health-related quality of life of**
31 **respiratory syncytial virus (RSV) infection among infants and their caregivers in**
32 **Europe (under review).** *Vaccine* 2022.
- 33 34. Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW: **Methods for the**
34 **Economic Evaluation of Health Care Programmes**, Fourth edn. Oxford: Oxford
35 University Press; 2015.
- 36 35. **HICP - annual data (average index and rate of change)**
37 [[https://ec.europa.eu/eurostat/databrowser/view/prc_hicp_aind/default/table?lang](https://ec.europa.eu/eurostat/databrowser/view/prc_hicp_aind/default/table?lang=en&category=prc.prc_hicp)
38 [=en&category=prc.prc_hicp](https://ec.europa.eu/eurostat/databrowser/view/prc_hicp_aind/default/table?lang=en&category=prc.prc_hicp)]
- 39 36. **ECU/EUR exchange rates versus national currencies**
40 [<https://ec.europa.eu/eurostat/databrowser/view/tec00033/default/table?lang=en>]

- 1 37. Janssen MF, Szende A, Cabases J, Ramos-Goni JM, Vilagut G, König HH: **Population**
2 **norms for the EQ-5D-3L: a cross-country analysis of population surveys for 20**
3 **countries.** *Eur J Health Econ* 2019, **20**(2):205-216.
- 4 38. Koskinen S, Lundqvist A, Ristiluoma N: **Health, functional capacity and welfare in**
5 **Finland in 2011.** In. Helsinki, Finland: National Institute for Health and Welfare (THL);
6 2012: 290.
- 7 39. Mao Z, Li X, Dacosta-Urbieta A, Billard MN, Wildenbeest J, Korsten K, Martinon-
8 Torres F, Heikkinen T, Cunningham S, Snape MD *et al*: **Economic burden and health-**
9 **related quality-of-life among infants with respiratory syncytial virus infection: A**
10 **multi-country prospective cohort study in Europe.** *Vaccine* 2023.
- 11 40. Zeevat F, Luttjeboer J, Paulissen JHJ, van der Schans J, Beutels P, Boersma C, Postma
12 MJ, Investigators R: **Exploratory Analysis of the Economically Justifiable Price of a**
13 **Hypothetical RSV Vaccine for Older Adults in the Netherlands and the United**
14 **Kingdom.** *J Infect Dis* 2022, **226**(Supplement_1):S102-S109.
- 15 41. Bilcke J, Beutels P: **Generating, Presenting, and Interpreting Cost-Effectiveness**
16 **Results in the Context of Uncertainty: A Tutorial for Deeper Knowledge and Better**
17 **Practice.** *Med Decis Making* 2022, **42**(4):421-435.
- 18 42. Briggs AC, K. Sculpher, M: **Decision Modelling for Health Economic Evaluation.**
19 Oxford: Oxford University Press; 2006.
- 20 43. Pieters Z, Strong M, Pitzer VE, Beutels P, Bilcke J: **A Computationally Efficient**
21 **Method for Probabilistic Parameter Threshold Analysis for Health Economic**
22 **Evaluations.** *Med Decis Making* 2020, **40**(5):669-679.
- 23 44. Egeskov-Cavling AM, Johannesen CK, Lindegaard B, Fischer TK: **Underreporting and**
24 **misclassification of RSV-coded hospitalization among adults in Denmark between**
25 **2015/16 to 2017/18.** *J Infect Dis* 2023.
- 26 45. Johannesen CK, Gideonse D, Osei-Yeboah R, Lehtonen T, Jollivet O, Cohen RA,
27 Urchueguía-Fornes A, Herrero-Silvestre M, López-Lacort M, Kramer R *et al*:
28 **Underreporting of respiratory syncytial virus-associated hospital admissions in five**
29 **European countries revealed through time series analysis.** *Under preparation (pre-*
30 *print available upon request)* 2024.
- 31 46. Cai W, Tolksdorf K, Hirve S, Schuler E, Zhang W, Haas W, Buda S: **Evaluation of using**
32 **ICD-10 code data for respiratory syncytial virus surveillance.** *Influenza Other Respir*
33 *Viruses* 2020, **14**(6):630-637.
- 34 47. Saez-Lopez E, Pechirra P, Costa I, Cristovao P, Conde P, Machado A, Rodrigues AP,
35 Guiomar R: **Performance of surveillance case definitions for respiratory syncytial**
36 **virus infections through the sentinel influenza surveillance system, Portugal, 2010**
37 **to 2018.** *Euro Surveill* 2019, **24**(45).
- 38 48. Hirve S, Crawford N, Palekar R, Zhang W, Group WRs: **Clinical characteristics,**
39 **predictors, and performance of case definition-Interim results from the WHO**
40 **global respiratory syncytial virus surveillance pilot.** *Influenza Other Respir Viruses*
41 2020, **14**(6):647-657.

- 1 49. Hodgson D, Pebody R, Panovska-Griffiths J, Baguelin M, Atkins KE: **Evaluating the**
2 **next generation of RSV intervention strategies: a mathematical modelling study**
3 **and cost-effectiveness analysis.** *BMC Med* 2020, **18**(1):348.
- 4 50. Herring WL, Zhang Y, Shinde V, Stoddard J, Talbird SE, Rosen B: **Clinical and**
5 **economic outcomes associated with respiratory syncytial virus vaccination in older**
6 **adults in the United States.** *Vaccine* 2022, **40**(3):483-493.
- 7 51. Appleby J, Devlin N, Parkin D: **NICE's cost effectiveness threshold.** *BMJ* 2007,
8 **335**(7616):358-359.
- 9 52. Gyrd-Hansen D: **Willingness to pay for a QALY.** *Health Econ* 2003, **12**(12):1049-1060.
- 10 53. Heini S: **Economic evaluations in adopting new vaccines in the Finnish national**
11 **vaccination programme.** University of Helsinki; 2017.
- 12 54. Schurer M, Matthijsse SM, Vossen CY, van Keep M, Horscroft J, Chapman AM,
13 Akehurst RL: **Varying Willingness to Pay Based on Severity of Illness: Impact on**
14 **Health Technology Assessment Outcomes of Inpatient and Outpatient Drug**
15 **Therapies in The Netherlands.** *Value Health* 2022, **25**(1):91-103.
- 16 55. Vallejo-Torres L, Garcia-Lorenzo B, Serrano-Aguilar P: **Estimating a cost-effectiveness**
17 **threshold for the Spanish NHS.** *Health Econ* 2018, **27**(4):746-761.
- 18 56. Woodruff RC, Melgar M, Pham H, Sperling LS, Loustalot F, Kirley PD, Austin E,
19 Yousey-Hindes K, Openo KP, Ryan P *et al*: **Acute Cardiac Events in Hospitalized Older**
20 **Adults With Respiratory Syncytial Virus Infection.** *JAMA Intern Med* 2024,
21 **184**(6):602-611.
- 22